Advances in Psychiatric Treatment (2009) 15: 242-249. doi: 10.1192/apt.bp.105.001834
© 2009 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in APT
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by McIsaac, S. A.
Right arrow Articles by Young, A. H.
PubMed
Right arrow Articles by McIsaac, S. A.
Right arrow Articles by Young, A. H.

Antiglucocorticoids in psychiatry{dagger}

Sean A. McIsaac, Åsa Westrin and Allan H. Young

Sean McIsaac studied for his Bachelor degree in biology at the University of British Columbia, Vancouver, Canada, where he is currently a research assistant at the Institute of Mental Health. He worked for the Wellington Lab, focusing on the interplay of lipid transporters in Alzheimer’s disease. His present work, with Professor Allan Young, follows his interest in the impact of endocrine dysfunction in psychiatric disorders. Åsa Westrin is a research psychiatrist in the Department of Clinical Neuroscience at Lund University, Sweden. Her main research interest involves stress-system alterations in depression and suicidal behaviour. Allan Young currently holds the LEEF Endowed Chair in Research in the Department of Psychiatry at the University of British Columbia, Vancouver, Canada, where he is also the Director of the Institute of Mental Health. His research interests focus on the causes and treatments for severe psychiatric illnesses, particularly mood disorders.

Correspondence: Correspondence Professor Allan Young, Institute of Mental Health, University of British Columbia, 5950 University Blvd, Vancouver, BC, V6T 2A1, Canada. Email: alyoung{at}interchange.ubc.ca

Significant evidence has accrued suggesting that the hypothalamic–pituitary–adrenal (HPA) axis plays a role in some psychiatric disorders. This article reviews the physiology of the HPA axis, evidence of dysfunction in this axis in psychiatric illnesses and the role that this dysfunction might play in pharmacological treatment resistance. Future therapeutic strategies that may potentially arise from these researches are briefly outlined.


Related articles in APT:

Targeting the HPA axis in major depression: does it work?: INVITED COMMENTARY ON... ANTIGLUCOCORTICOIDS IN PSYCHIATRY
Stephan Claes
APT 2009 15: 250-252. [Abstract] [Full Text]  

Eclecticism
Joe Bouch
APT 2009 15: 241. [Full Text]  



This article has been cited by other articles:


Home page
 Adv. Psychiatr. Treat.Home page
S. Claes
Targeting the HPA axis in major depression: does it work?: INVITED COMMENTARY ON... ANTIGLUCOCORTICOIDS IN PSYCHIATRY
Adv. Psychiatr. Treat., July 1, 2009; 15(4): 250 - 252.
[Abstract] [Full Text] [PDF]